Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells

Deniz Cansen Kahraman, Gilles Hanquet, Loïc Jeanmart, Steve Lanners, Peter Šramel, Andrej Boháč, Rengul Cetin-Atalay

Research output: Contribution to journalArticlepeer-review

Abstract

Bioactivities of quinoides 1-5 and VEGFR2 TKIs 6-10 in hepatocellular cancer (HCC) and cancer stem cells (HCSCs) were studied. The compounds exhibited IC50 values in μM concentrations in HCC cells. Quinoide 3 was able to eradicate cancer stem cells, similar to the action of the stem cell inhibitor DAPT. However, the more cytotoxic VEFGR TKIs (IC50: 0.4-3.0 μM) including sorafenib, which is the only FDA approved drug for the treatment of HCC, enriched the hepatocellular cancer stem cell population by 2-3 fold after treatment. An aggressiveness factor (AF) was proposed to quantify the characteristics of drug candidates for their ability to eradicate the CSC subpopulation. Considering the tumour heterogeneity and marker positive cancer stem cell like subpopulation enrichment upon treatments in patients, this study emphasises the importance of the chemotherapeutic agent choice acting differentially on all the subpopulations including marker-positive CSCs.

Original languageEnglish
Pages (from-to)81-87
Number of pages7
JournalMedChemComm
Volume8
Issue number1
Early online date7 Oct 2016
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells'. Together they form a unique fingerprint.

Cite this